347 related articles for article (PubMed ID: 15127371)
21. Understanding the burden of pneumococcal disease in adults.
Blasi F; Mantero M; Santus P; Tarsia P
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():7-14. PubMed ID: 22882668
[TBL] [Abstract][Full Text] [Related]
22. Pneumolysin as a vaccine and drug target in the prevention and treatment of invasive pneumococcal disease.
Cockeran R; Anderson R; Feldman C
Arch Immunol Ther Exp (Warsz); 2005; 53(3):189-98. PubMed ID: 15995579
[TBL] [Abstract][Full Text] [Related]
23. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia.
Jones RN; Jacobs MR; Sader HS
Int J Antimicrob Agents; 2010 Sep; 36(3):197-204. PubMed ID: 20558045
[TBL] [Abstract][Full Text] [Related]
24. [An update of Streptococcus pneumoniae: from genomic to clinic].
Wintenberger C
Med Mal Infect; 2010 Oct; 40(10):605-9. PubMed ID: 20934286
[No Abstract] [Full Text] [Related]
25. Antibiotic use: the crystal ball for predicting antibiotic resistance.
Pantosti A; Moro ML
Clin Infect Dis; 2005 May; 40(9):1298-300. PubMed ID: 15825032
[No Abstract] [Full Text] [Related]
26. Quinolone resistance among pneumococci: therapeutic and diagnostic implications.
Low DE
Clin Infect Dis; 2004 May; 38 Suppl 4():S357-62. PubMed ID: 15127370
[TBL] [Abstract][Full Text] [Related]
27. Emergence of fluoroquinolone-resistant Streptococcus pneumoniae in Lebanon: a report of three cases.
Naba MR; Araj GF; Baban TA; Tabbarah ZA; Awar GN; Kanj SS
J Infect Public Health; 2010; 3(3):113-7. PubMed ID: 20869671
[TBL] [Abstract][Full Text] [Related]
28. A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae.
Rzeszutek M; Wierzbowski A; Hoban DJ; Conly J; Bishai W; Zhanel GG
Int J Antimicrob Agents; 2004 Aug; 24(2):95-104. PubMed ID: 15288306
[TBL] [Abstract][Full Text] [Related]
29. Antimicrobial susceptibilities of Streptococcus pneumoniae isolated from adult patients with community-acquired pneumonia in Japan.
Ishida T; Maniwa K; Kagioka H; Hirabayashi M; Onaru K; Tomioka H; Hayashi M; Tomii K; Gohma I; Ito Y; Hirai T; Ito I; Mishima M
Respirology; 2008 Mar; 13(2):240-6. PubMed ID: 18339022
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Jones RN; Fritsche TR; Sader HS
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
[TBL] [Abstract][Full Text] [Related]
31. [In vitro resistance rates of Streptococcus pneumoniae and Haemophilus influenzae clinical isolates to the antibiotics used in therapy].
Uncu H; Colakoğlu S; Turunç T; Demiroğlu YZ; Arslan H
Mikrobiyol Bul; 2007 Jul; 41(3):441-6. PubMed ID: 17933256
[TBL] [Abstract][Full Text] [Related]
32. Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska.
Moore MR; Hyde TB; Hennessy TW; Parks DJ; Reasonover AL; Harker-Jones M; Gove J; Bruden DL; Rudolph K; Parkinson A; Butler JC; Schuchat A
J Infect Dis; 2004 Dec; 190(11):2031-8. PubMed ID: 15529269
[TBL] [Abstract][Full Text] [Related]
33. The coming of age of niche vaccines? Effect of vaccines on resistance profiles in Streptococcus pneumoniae.
McGee L
Curr Opin Microbiol; 2007 Oct; 10(5):473-8. PubMed ID: 17936680
[TBL] [Abstract][Full Text] [Related]
34. Emergence of rifampin-resistant Streptococcus pneumoniae as a result of antimicrobial therapy for penicillin-resistant strains.
van Tilburg PM; Bogaert D; Sluijter M; Jansz AR; de Groot R; Hermans PW
Clin Infect Dis; 2001 Oct; 33(8):e93-6. PubMed ID: 11550121
[TBL] [Abstract][Full Text] [Related]
35. Pneumococcal bacteraemia in Belgium (1994 2004): the pre-conjugate vaccine era.
Flamaing J; Verhaegen J; Vandeven J; Verbiest N; Peetermans WE
J Antimicrob Chemother; 2008 Jan; 61(1):143-9. PubMed ID: 17999974
[TBL] [Abstract][Full Text] [Related]
36. Antibiotic susceptibility according to genotype of penicillin-binding protein and macrolide resistance genes, and serotype of Streptococcus pneumoniae isolates from community-acquired pneumonia in children.
Chiba N; Kobayashi R; Hasegawa K; Morozumi M; Nakayama E; Tajima T; Iwata S; Ubukata K;
J Antimicrob Chemother; 2005 Oct; 56(4):756-60. PubMed ID: 16131518
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for drug-resistant Streptococcus pneumoniae and antibiotic prescribing practices in outpatient community-acquired pneumonia.
Jenkins TC; Sakai J; Knepper BC; Swartwood CJ; Haukoos JS; Long JA; Price CS; Burman WJ
Acad Emerg Med; 2012 Jun; 19(6):703-6. PubMed ID: 22632455
[TBL] [Abstract][Full Text] [Related]
38. Decreasing rates of resistance to penicillin, but not erythromycin, in Streptococcus pneumoniae after introduction of a policy to restrict antibiotic usage in Taiwan.
Hsueh PR
Clin Microbiol Infect; 2005 Nov; 11(11):925-7. PubMed ID: 16216110
[TBL] [Abstract][Full Text] [Related]
39. Measuring and interpreting associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae.
Lipsitch M
Clin Infect Dis; 2001 Apr; 32(7):1044-54. PubMed ID: 11264033
[TBL] [Abstract][Full Text] [Related]
40. Antibiotic resistance in Latin America: a cause for alarm.
Valenzuela MT; de Quadros C
Vaccine; 2009 Aug; 27 Suppl 3():C25-8. PubMed ID: 19540634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
